Pancreatic Ductal Adenocarcinoma (PDAC) Clinical Trials in Beijing, Beijing Municipality
5 recruitingBeijing, Beijing Municipality, China
Showing 1–5 of 5 trials
Recruiting
Phase 1Phase 2
A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy
Pancreatic Ductal Adenocarcinoma (PDAC)
Shenzhen Majory Biotechnology Co., Ltd.45 enrolled4 locationsNCT07235202
Recruiting
Phase 1Phase 2
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
Pancreatic CancerGastric CancerNon-small Cell Lung Cancer (NSCLC)+2 more
EMD Serono Research & Development Institute, Inc.250 enrolled81 locationsNCT06710132
Recruiting
Phase 2
Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Solid Tumor+1 more
Guangzhou JOYO Pharma Co., Ltd210 enrolled1 locationNCT06895031
Recruiting
Phase 1Phase 2
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Breast CancerLiver CancerNon-small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech85 enrolled1 locationNCT07410494
Recruiting
Phase 2
A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma
Pancreatic Ductal Adenocarcinoma (PDAC)
Qilu Pharmaceutical Co., Ltd.120 enrolled1 locationNCT06261359